Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Gilead Sciences is a research-based biopharmaceutical company focused on antiviral therapies, with dominant franchises in HIV (Biktarvy, Descovy generating ~$15B annually), hepatitis C (legacy franchise), and oncology (Trodelvy, Yescarta). The company operates a high-margin pharmaceutical model with 87% gross margins, driven by patent-protected specialty drugs sold primarily in developed markets (US ~70% of revenue), and maintains competitive moat through extensive clinical trial infrastructure and strong payer relationships.
Gilead generates revenue through patent-protected specialty pharmaceuticals sold via wholesale distributors and specialty pharmacies. Pricing power derives from clinical superiority (Biktarvy has 50%+ HIV market share due to efficacy/tolerability), high switching costs in chronic disease management, and payer formulary positioning. The company invests 15-20% of revenue in R&D to maintain pipeline, with operating leverage from fixed R&D/SG&A spread across growing product sales. Gross margins of 87% reflect minimal COGS for small-molecule and biologic manufacturing, with profitability driven by volume growth and price increases (typically 5-7% annually in US before rebates).
HIV franchise growth trajectory - Biktarvy volume trends, market share gains/losses, lenacapavir (twice-yearly injectable) Phase 3 trial results and launch timing
Oncology pipeline progress - Trodelvy label expansions (lung cancer, bladder cancer trials), CAR-T manufacturing capacity and reimbursement trends
Patent cliff visibility - Biktarvy generic entry timing (2031-2033), lifecycle management strategies, new molecular entity approvals
Capital allocation - dividend sustainability ($3.04/share, 3.5% yield), M&A activity (recent $4.3B Immunomedics acquisition), share buyback pace
COVID-19 antiviral demand - Veklury sales volatility based on hospitalization rates and competitive dynamics with Paxlovid
Patent cliff concentration - Biktarvy represents ~$12B in annual revenue with LOE 2031-2033; generic entry could eliminate 70-80% of sales within 12 months based on historical HIV generic erosion patterns
Pricing pressure intensification - IRA drug price negotiations (Gilead products likely targets post-2026), PBM rebate inflation (currently 40-50% of list price), potential Medicare Part D redesign reducing manufacturer liability
Biosimilar and generic competition - Yescarta faces CAR-T competition from Bristol-Myers, Novartis; hepatitis C franchise already commoditized with 90%+ price erosion since peak
HIV market share erosion - ViiV Healthcare (GSK) cabotegravir long-acting injectable gaining traction; Merck's islatravir development; potential best-in-class entrants with superior resistance profiles
Oncology pipeline execution - Trodelvy competing in crowded breast cancer market with antibody-drug conjugates from Daiichi Sankyo (Enhertu), AstraZeneca; CAR-T manufacturing scale disadvantages versus Novartis, BMS
Dividend sustainability risk - $3B annual dividend commitment requires consistent FCF generation; potential cut if Biktarvy erosion accelerates without pipeline offsets
M&A integration risk - history of large acquisitions (Kite Pharma $12B, Immunomedics $21B) with mixed ROI; future deals may be necessary to offset patent cliffs but carry execution risk
low - Pharmaceutical demand is non-discretionary and largely insulated from GDP fluctuations. HIV and oncology patients continue therapy regardless of economic conditions. However, severe recessions can impact: (1) insurance coverage rates and Medicaid enrollment (positive for volume, negative for pricing), (2) hospital budgets affecting CAR-T utilization, (3) clinical trial enrollment and R&D timelines.
Rising rates create moderate headwinds through two mechanisms: (1) valuation multiple compression as high-margin pharma stocks trade at premium P/E ratios (currently 14.9x EV/EBITDA) and higher discount rates reduce NPV of long-duration pipeline assets, (2) increased financing costs for M&A activity, though Gilead maintains strong balance sheet with minimal net debt. However, $10B annual free cash flow provides substantial cushion. Rate sensitivity is lower than growth biotech due to established profitability.
minimal - Gilead has negligible credit exposure as pharmaceutical sales are primarily to investment-grade wholesalers (McKesson, AmerisourceBergen, Cardinal Health) with 30-60 day payment terms. Government payers (Medicare Part D, Medicaid) represent ~40% of revenue with reliable payment. No meaningful loan portfolio or credit-dependent customer base.
value/dividend - Gilead attracts income-focused investors seeking 3.5% dividend yield with 41% ROE and stable cash generation, plus value investors drawn to 6.5x P/S ratio (discount to pharma peers at 8-10x) based on patent cliff concerns being overestimated. Recent 46% one-year return reflects rotation from growth to profitable healthcare. Not a growth stock given 2.4% revenue growth, but appeals to investors betting on pipeline inflection (lenacapavir, oncology expansion) driving rerating.
moderate - Beta typically 0.7-0.9 (lower than market). Stock exhibits low day-to-day volatility due to predictable prescription revenue, but experiences sharp moves on pipeline data (±10-15% on Phase 3 readouts), M&A announcements, and pricing policy changes. Recent 23.8% three-month gain reflects above-average volatility during sector rotation.
